Taysha Gene Therapies, Inc. (TSHA): Total Liabilities
$96.38M
As of 2025-12-31
$83.17M
As of 2026-06-30
-8.4%
3-year compound annual growth
+66.3%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $96.38M | +8.5% | 2026-03-19, Balance as of period end |
| 2024-12-31 | $88.84M | -9.2% | 2026-03-19, Balance as of period end |
| 2023-12-31 | $97.79M | -22.0% | 2025-02-26, Balance as of period end |
| 2022-12-31 | $125.33M | +5.7% | 2024-03-19, Balance as of period end |
| 2021-12-31 | $118.57M | n/m | 2023-03-28, Balance as of period end |
| 2020-12-31 | $7.58M | n/m | 2022-03-31, Balance as of period end |
| 2019-12-31 | $150.0K | n/a | 2021-03-03, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | $96.38M | +8.5% |
| Curis Inc (CRIS) | 2025-12-31 | $14.50M | -69.3% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $17.20M | +47.7% |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $105.67M | -18.8% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $53.19M | -11.9% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $69.24M | +91.2% |
| Relay Therapeutics, Inc. (RLAY) | 2025-12-31 | $54.27M | -42.0% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $91.52M | n/m |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $64.95M | +69.7% |
Compare TSHA, CRIS, ACOG, TCRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗